B rachydactyly (BD) is a term used to describe inherited anomalies of the hands generally characterised by shortened phalanges or metacarpals. Initially, the brachydactylies were grouped into five different classes (A-E), with three subtypes of A. 1 Later work revised and extended the classification of BD. 2 3 In type A, shortening is primarily confined to the middle phalanges. Subtype A1 (BDA1, OMIM 112500) is distinguished by hypoplastic middle phalanges (especially the 2nd and 5th digits), with either distal or terminal symphalangism depending on the severity. In addition, shortening of the proximal phalanges of the thumb, the metacarpals, metatarsals, or the big toe are also observed in these patients. Short stature is often associated with BDA1 patients.
Despite being the first syndrome described with Mendelian autosomal dominant inheritance in 1903, 4 , the genetic aetiology of BDA was not reported until 2001. 5 Suspecting that cell proliferation or differentiation factors could be the culprit causing BDA1, our group screened markers near several candidate genes in two families diagnosed with BDA1. No linkage was observed. 6 We also chose to look for mutations of the PAX3 genes in these families by direct sequencing of all the exons, but no significant mutation was identified (unpublished data).
In 2000, a locus for BDA1 was mapped to 2q35-q36 in two unrelated Chinese families. 7 Refined mapping and mutation screening of candidate genes in the region by the same group identified missense mutations in the Indian Hedgehog gene (IHH) of the affected subjects in three unrelated families. 5 The missense mutations, located at the amino terminus of the IHH protein, are conserved among the Hedgehog family proteins. Local and long range cell proliferation signalling functions were suggested to reside within the amino-terminus domain. Interestingly, ROR2 and CDMP1 have been identified to cause brachydactyly types B and C, respectively. 8 9 The genes are important in chondrocyte proliferation and differentiation and joint morphogenesis.
MATERIALS AND METHODS
The finding of IHH mutations in BDA1 patients led us to examine this gene in the two BDA1 families we previously studied. 6 We searched GenBank and extracted the genomic DNA sequence (NT_005289) using the cDNA sequence of IHH. IHH consists of three exons and spans approximately 5.5 kb of genomic DNA. The exon/intron boundaries of the three exons were identified and primers specifically targeting the splice sites and coding regions were designed using Oligo 4.1 Primer Analysis Software ( © Rychlik 1992) for polymerase chain reaction (PCR) amplification and sequencing. PCR primers used are as follows 5′ to 3′: 1F (CGACGCGCCTGCCCATCA), 2F (TCCTCCGGCTGATTTCGCTC), 2R (TTCTCGGCACTACTC-CTCCT), 3F (CAAGGGAGGGTCGTTGTGAC), 3R (GGAC-CCAGTACAGCAGTTCC). We also used primer 1R as described by Gao et al. 5 The three exons of IHH were then amplified by standard PCR and examined by electrophoresis on 3% MetaPhor ® agarose gels. Shrimp alkaline phosphatase (1 U) and exonuclease I (10 U) were used to remove excess dNTPs and primers from our samples. We then sequenced the exons using BigDye Terminator (v.1) reagent following the manufacturer's protocol (Applied Biosystems, Foster City, CA). After purification through Sephadex ® G-50 Fine columns, the sequenced products were run on an ABI Prism 3100 automated sequencer and analysed with the ABI Sequencing Analysis 3.7 software. Any changes noted in the patients' sequences were confirmed by sequencing in the reverse direction. The IHH gene was sequenced for all affected and unaffected people in the study.
RESULTS AND DISCUSSION
Our sequencing results identified a missense mutation in IHH in all affected members of family II, a family of Mexican descent ( fig 1A) . The missense mutation involved a 284A→G transition in exon 1 of these patients resulting in a Glu95→Gly mutation ( fig 1B) . Gao et al 5 reported a mutation of a different nucleotide (283G→A) in the same codon, resulting in a Glu95→Lys mutation. The recurrent mutation found within the same codon among unrelated patients of different ethnic backgrounds further supports the functional importance of Glu95 in the IHH peptide. The codon, Glu95, is conserved among hedgehog proteins and is suspected to play an important role in binding to the receptor for downstream cell cycle signalling. Gao et al 5 hypothesised that the novel mutations in IHH would cause BDA1 because of their position in the amino-terminal signalling domain. Amino acid changes in this domain of the closely related protein Sonic Hedgehog (SHH) have been shown to elicit a deleterious effect in SHH Key points
• Brachydactyly type A1 (BDA1) is particularly interesting because it is the first syndrome characterised by Mendelian autosomal dominant inheritance.
• Three different missense mutations in the Indian Hedgehog gene (IHH) were recently identified in three BDA1 families. Another group showed linkage to an 11 cM region on chromosome 5p13.
• In one of our BDA1 families, we identified a missense mutation in IHH in all patients at a similar position to that previously reported. In another family, we excluded linkage to the 5p13 region and identified a polymorphism in IHH that segregated independent status. • These data support the existence of a third locus for BDA1.
binding with its receptor Patched (PTC), also a receptor for IHH. [10] [11] [12] Therefore, the three IHH mutations are also likely to disrupt binding of the IHH protein to PTC. If the missense mutations cause complete loss of binding, then BDA1 would be caused by haploinsufficiency of the wild type protein. The mutations may also result in partial loss or altered binding, the latter predicted to cause a gain of function effect. Our finding, together with that of Gao et al, 5 suggests the carboxyl side chain of Glu95 is vital to IHH protein function. Functional assays will elucidate the effect of these mutations.
Before discovery of IHH mutations, Fukushima et al 13 reported a case with an apparently balanced 5q11.2 and 17q23 translocation in a girl with BDA1 and Klippel-Feil syndrome. Armour et al 14 conducted a genome-wide linkage study on a four generation BDA1 family of Canadian descent, with special attention to chromosomes 5 and 17. Their study identified linkage of BDA1 to an 11 cM region on chromosome 5p13.3-13.2. The region contains two notable candidate genes, cadherin-6 (CDH6) and natriuretic peptide receptor C (NPR3), whose proteins are suggested to have roles in osteoclast differentiation and skeletal development.
Before the mutations in IHH were published, we examined markers (D5S819, D5S1986, D5S477, D5S1506, and D5S663) for our two BDA1 families to determine if there was linkage to the 5p13.3-p13.2 region. In family I, the same haplotype from I.1 is transmitted to affected and unaffected subjects in the second (II.1, II.2, II.4, and II.5) and third generations (III.2 and III.3) (fig 2A) . However, affected subject III.1 did not inherit any of the chromosome 5 markers from the affected grandparent, I.1. Taken together, our family I does not show linkage to the 5p13.3-p13.2 candidate BDA1 region.
Direct sequencing analysis detected no significant changes in the exons and splice sites of IHH in affected members of family I. We did detect a 753T→C transition resulting in a silent variant (Pro251→Pro) and producing a novel restriction enzyme Bsp1286I site. Testing of all family members showed that the Bsp1286I -(T) allele segregated independently of BDA1 in the family (members II.5, II.6, III.2, and III.3), therefore excluding IHH as the disease causing gene ( fig 2B) . Our previous study using various genetic markers on several other chromosomes, and the chromosome 5 markers reported here, excluded non-paternity for II.6. 6 Since the variant is within exon 3 and IHH is small (5.5 kb), it is unlikely that other changes in the introns of IHH are causing BDA1 in family I.
Exclusion of linkage to both IHH and chromosome 5p13.3-13.2 in our BDA1 family I points to the existence of yet a third locus for BDA1. SNP linkage analysis of the receptors of IHH, its target genes, or the downstream targets for CDH6 or NPR3 are future studies that could uncover the disease gene in our family I. 
